Lacosamide Ucb (Lacosamide)

Lacosamide works by enhancing the slow inactivation of voltage‑gated sodium channels, which stabilizes neuronal membranes and limits repetitive firing. Additionally, it binds to the protein CRMP‑2, influencing neuronal development pathways that may further contribute to its anticonvulsant activity.

The specific dose and infusion rate of Lacosamide Ucb are determined by the prescribing clinician based on the patient’s clinical condition, age, renal and hepatic function, and response to therapy. Healthcare professionals should follow local prescribing guidelines and adjust as needed.

Safety data for lacosamide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation and binding CRMP‑2—differs from many traditional antiepileptics that target fast inactivation. This can provide additive seizure control when combined with other agents, and it may have a more favorable interaction profile compared with some enzyme‑inducing drugs.

Lacosamide Ucb should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside the recommended range.

Lacosamide Ucb is administered intravenously by a healthcare professional. The infusion rate and total daily dose are individualized according to the patient’s clinical needs and are typically given over a period of minutes to hours, following the prescribing information.

Serious risks include cardiac conduction abnormalities such as atrioventricular block or other arrhythmias, severe skin reactions like Stevens‑Johnson syndrome, and hypersensitivity reactions that may be life‑threatening. Patients should be monitored for these events, especially during initiation and dose adjustments.

Lacosamide Ucb is contraindicated in patients with known hypersensitivity to lacosamide or any of the formulation excipients. Caution is also advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking medications that may cause dangerous interactions.